Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer

Bibliography

• Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014;27:16-25
   PubMed Web of Science ®Google Scholar
• Petersen SL. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Dan Med Bull 2007;54(2):112-39
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature reviews Cancer 2008;8(4):299-308
   PubMed Web of Science ®Google Scholar
• Mullen JT, Tanabe KK. Viral oncolysis. Oncologist 2002;7(2):106-19
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64
   PubMed Web of Science ®Google Scholar
• Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 2015;263(1):68-89
   PubMed Web of Science ®Google Scholar
• Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009;69(12):4941-4
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Kufer P, Baeuerle PA, et al. Blinatumomab: a historical perspective. Pharmacol Ther 2012;136(3):334-42
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005;115(1):98-104
   PubMed Web of Science ®Google Scholar
• Goebeler M, Viardot A, Kufer P, et al. Final Results from a Phase 1 Study of Blinatumomab in Patients With Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL). Hematol Oncol 2013;31(S1):151-200
   PubMedGoogle Scholar
• Zimmerman Z, Maniar T, Nagorsen D. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE(R)) antibody construct blinatumomab as a potential therapy. Int immunol 2015;27(1):31-7
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29(18):2493-8
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120(26):5185-7
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Dombret H, Bonifacio M, et al. BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL). Blood 2014;124(21):379-9
   Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, et al.Phase II. Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia. J Clinical Oncol 2014;32(36):4134-40
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2014
   PubMed Web of Science ®Google Scholar
• von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment. 2014;124(21):2292-2
   Google Scholar
• Viardot A, Goebeler M, Hess G, et al. Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma with the Bispecific T-Cell Engager (BiTE®) Antibody Construct Blinatumomab: Primary Analysis Results from an Open-Label, Phase 2 Study. Blood 2014;124(21):4460-0
   Web of Science ®Google Scholar
• Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014;123(3):356-65
   PubMed Web of Science ®Google Scholar
• Cioffi M, Dorado J, Baeuerle PA, Heeschen C. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 2012;18(2):465-74
   PubMed Web of Science ®Google Scholar
• Herrmann I, Baeuerle PA, Friedrich M, et al. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS ONE 2010;5(10):e13474
   PubMed Web of Science ®Google Scholar
• Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013;17(3):385-92
   PubMed Web of Science ®Google Scholar
• Peng L, Oberst MD, Huang J, et al. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. PLoS One 2012;7(5):e36412
   PubMed Web of Science ®Google Scholar
• Friedrich M, Raum T, Lutterbuese R, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 2012;11(12):2664-73
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, Gornall H, Baldan V. CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev 2014;257(1):91-106
   PubMed Web of Science ®Google Scholar
• Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012;119(26):6226-33
   PubMed Web of Science ®Google Scholar
• Offner S, Hofmeister R, Romaniuk A, et al. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006;43(6):763-71
   PubMed Web of Science ®Google Scholar